Gilead Sciences Q3 FY26: where the revenue came from and where it went
The whole income statement of Gilead Sciences for this quarter, as one diagram: what earned the revenue, and what it went on.
- Period
- Jul 1 – Sep 30, 2026
Revenue$8.30B
+7% year over year
Gross profit$6.73B
81% margin
Operating profit$3.46B
42% margin
Net profit$2.43B
29% margin
The numbers
| Item | Value | Share of revenue | Year over year |
|---|---|---|---|
| Revenue | 8.30 | 100% | +7% |
| Biktarvy | 3.77 | 45% | |
| Other revenue | 1.84 | 22% | |
| Total liver disease | 0.88 | 11% | |
| Trodelvy | 0.46 | 6% | |
| Total cell therapy | 0.42 | 5% | |
| Yescarta | 0.35 | 4% | |
| Sofosbuvir/Velpatasvir | 0.30 | 4% | |
| Genvoya | 0.29 | 3% | |
| Cost of revenue | −1.57 | 19% | |
| Gross profit | 6.73 | 81% margin | +1pp |
| SG&A | −1.64 | 20% | +2pp |
| Other | −1.63 | 19% | +0pp |
| Operating profit | 3.46 | 42% margin | −1pp |
| Interest & other costs | −0.40 | ||
| Tax | −0.63 | ||
| Net profit | 2.43 | 29% margin | −10pp |
146 of 418 companies, most recently reported first
New results in your inbox
When a big company reports, we send you a link to its diagram before anyone has time to comment on it. This is a mailing list, not an account: it does not open the diagrams by itself. No spam, one-click unsubscribe.
Drag or use the arrow keys to see the rest